Sagimet Biosciences Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount
Sagimet Biosciences Inc. (SGMT) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount of $156.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-11.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2026-03-11
- Sagimet Biosciences Inc. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2025 was $156.00K, a 92.11% decline from fiscal 2024.
- Sagimet Biosciences Inc. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2024 was $1.98M.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 12 month |
|---|---|
| 2025-12-31 | $156.00K 10-K · filed 2026-03-11 |
| 2024-12-31 | $1.98M 10-K · filed 2026-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |